Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Henlius Biotech IPO Raises Below-Target $410m

Sep 24 2019

• By Penelope MacRae

IPO — Shanghai Henlius Biotech’s IPO has raised $410m • Source: Shutterstock

Related Content

Chinese Biosimilar Boom Is Heralded By First Approval

Feb 28 2019

Henlius Has First ‘China-Developed’ Biosimilar Accepted For EMA Review

Jun 25 2019

Trend Revising? Biotech IPOs Slow Sharply In HK While Shanghai's STAR Shines

Aug 21 2019

Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In

Aug 03 2018

Related Companies

Shanghai Henlius Biotech Co. Ltd.

Additional Topics

China Asia Pacific Strategy Biosimilars BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window